Answers are grounded in this paper and cite their sources.
India bears a pneumococcal disease burden, with serogroup 6 contributing to invasive pneumococcal disease, acute otitis media, and nasopharyngeal carriage. Serotype 6B is included in several pneumococcal conjugate vaccines, with evidence suggesting cross-protection against serotype 6A. This systematic review and meta-analysis evaluated serotype 6A-specific immune responses following vaccination with 6B-containing pneumococcal conjugate vaccines. Databases were searched for studies reporting IgG geometric mean concentrations, proportions achieving IgG ≥ 0.35 µg/mL, and opsonophagocytic activity titers. Forty-three studies met inclusion criteria; eight contributed quantitative data. Overall, 6B-containing vaccines elicited measurable cross-reactive IgG and functional responses against serotype 6A. Booster-containing 3 + 1 schedules showed numerically higher responses than 3 + 0 schedules, with pooled IgG GMCs of 1.63 vs. 0.59 µg/mL, proportions achieving IgG ≥ 0.35 µg/mL of 92.78% vs. 65.38%, and OPA GMTs of 984.6 vs. 169.2, respectively. The protocol was registered in PROSPERO (CRD420251134118). These findings support 6B-mediated cross-reactive immunogenicity, particularly following booster dosing in vaccinated children.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: